Surgery
Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease
Journal of Surgical Oncology 2023 September [Link] Daniel L Miller, Christopher S Parks, Brittany Ange, Ioana R Bonta, Patricia T Rich Abstract Objectives: Pleural metastasis has extremely poor prognosis. Resection of pleural implants with infusion of intrathoracic hyperthermic chemotherapy may offer a survival advantage in selected patients. We evaluated the safety and efficacy of hyperthermic…
Read More2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma
Annals of Surgical Oncology 2023 July 23 [Link] Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Shigeki Kusamura, Marcello Deraco Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive primary peritoneal disease, with recommended treatment, in eligible patients, of a combination of complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). As…
Read MoreCisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform
Scientific Reports 2023 July 19 [Link] Steven D Forsythe, Richard A Erali, Nicholas Edenhoffer, William Meeker, Nadeem Wajih, Cecilia R Schaaf, Preston Laney, Cristian D Vanezuela, Wencheng Li, Edward A Levine, Shay Soker, Konstantinos I Votanopoulos Abstract Peritoneal mesothelioma (PM) is a rare malignancy with poor prognosis, representing about 10-15% of all mesothelioma cases. Herein…
Read MoreGene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
Genes, Chromosomes, & Cancer 2023 July 8 [Link] Maymun Jama, Min Zhang, Charlotte Poile, Apostolos Nakas, Annabel Sharkey, Joanna Dzialo, Alan Dawson, Kudazyi Kutywayo, Dean A Fennell, Edward J Hollox Abstract Malignant pleural mesothelioma (MPM), a rare cancer a long latency period (up to 40 years) between asbestos exposure and disease presentation. The mechanisms coupling…
Read MoreMesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma
Biochemical Pharmacology 2023 August [Link] Valentina Coccè, Mara Bonelli, Silvia La Monica, Roberta Alfieri, Luisa Doneda, Eleonora Martegani, Giulio Alessandri, Costanza Annamaria Lagrasta, Aldo Giannì, Valeria Sordi, Francesco Petrella, Leda Roncoroni, Francesca Paino, Augusto Pessina Abstract Malignant pleural mesothelioma is an asbestos-related tumor originating in mesothelial cells of the pleura that poorly responds to chemotherapeutic…
Read MoreHigh-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?
Indian Journal of Surgical Oncology 2023 June [Link] Praveen Kammar, Niharika Garach, Aditi Bhatt, Jay Anam, Vashisth Maniar, Adwaita Gore, Sanket Mehta Abstract Objective: To evaluate the feasibility, tolerance, and efficacy of OMCT (oral metronomic chemotherapy) after CRS + HIPEC for peritoneal mesothelioma in patients with poor prognostic factors: PCI > 20, incomplete CRS, poor…
Read MoreTarget Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
International Journal of Molecular Sciences 2023 May 23 [Link] Federica Borea, Marika A Franczak, Maria Garcia, Matteo Perrino, Nadia Cordua, Ryszard T Smolenski, Godefridus J Peters, Rafal Dziadziuszko, Armando Santoro, Paolo A Zucali, Elisa Giovannetti Abstract Malignant Pleural Mesothelioma (MPM) is a rare neoplasm that is typically diagnosed in a locally advanced stage, making it…
Read MoreComparison of video-assisted pleurectomy/decortication surgery plus hyperthermic intrathoracic chemotherapy with VATS talc pleurodesis for the treatment of malignant pleural mesothelioma: A pilot study
Heliyon 2023 May 25 [Link] Marcello Migliore, Maria Fiore, Tommaso Filippini, Rosario Tumino, Mara Sabbioni, Corrado Spatola, Riccardo Polosa, Paolo Vigneri, Marco Nardini, Sergio Castorina, Francesco Basile, Margherita Ferrante Abstract Hyperthermic intrathoracic chemotherapy (HITHOC) adjunct to surgery for Malignant Pleural Mesothelioma (MPM) has no definite role. The primary objective of this pilot-trial was to evaluate…
Read MoreCytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes
Journal of Surgical Oncology 2023 May 30 [Link] Melina Deban, Kadhim Taqi, Gregory C Knapp, Mikael Soucisse, Matt Curry, Lucas Sidéris, Pierre Dubé, Maher Al Khaldi, Nicole Jedrzejko, Geoff Porter, Carman Giacomantonio, Trevor Hamilton, Andrea MacNeill, Lloyd Mack, Antoine Bouchard-Fortier Abstract Introduction: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive…
Read MorePrognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Langenbeck’s Archives of Surgery 2023 May 6 [Link] Yasemin Yildirim, Selman Sokmen, Ali Durubey Cevlik, Tayfun Bisgin, Berke Manoglu, Funda Obuz Abstract Purpose: A valid comparison of immune function among different patients with different primary pathologies or even with different tumour burdens requires the common use of a reliable assessment of the patient’s condition. The…
Read More